Mitochondrial dysfunction and Alzheimer’s disease: prospects for therapeutic intervention

키워드

참고문헌 (84)

1. Anand R, "Therapeutics of Alzheimer's disease : Past, present and future", Neuropharmacology, 76(Pt A), pp.27~50 (2014)
2. Perry G, "Oxidative damage in Alzheimer's disease : the metabolic dimension", Int J Dev Neurosci, 18, pp.417~421 (2000)
3. Schmitt K, "Insights into mitochondrial dysfunction : aging, amyloid-beta, and tau-A deleterious trio", Antioxid Redox Signal, 16, pp.1456~1466 (2012)
4. Yao J, "Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease", Proc Natl Acad Sci U S A, 106, pp.14670~14675 (2009)
5. Swerdlow RH, "The Alzheimer's disease mitochondrial cascade hypothesis", J Alzheimers Dis 20 Suppl, 2, pp.S265~279 (2010)
6. Hauptmann S, "Mitochondrial dysfunction : an early event in Alzheimer pathology accumulates with age in AD transgenic mice", Neurobiol Aging, 30, pp.1574~1586 (2009)
7. Shulman RG, "Energetic basis of brain activity : implications for neuroimaging", Trends Neurosci, 27, pp.489~495 (2004)
8. Mao P, "Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease : implications for early intervention and therapeutics", Biochim Biophys Acta, 1812, pp.1359~1370 (2011)
9. Keil U, "Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis", J Biol Chem, 279, pp.50310~50320 (2004)
10. Eckert GP, "Mitochondrial dysfunction—a pharmacological target in Alzheimer's disease", Mol Neurobiol, 46, pp.136~150 (2012)
11. Johri A, "Mitochondrial dysfunction in neurodegenerative diseases", J Pharmacol Exp Ther, 342, pp.619~630 (2012)
12. Moreira PI, "Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology", Biochim Biophys Acta, 1802, pp.2~10 (2010)
13. Müller WE, "Mitochondrial dysfunction : common final pathway in brain aging and Alzheimer’s disease—therapeutic aspects", Mol Neurobiol, 41, pp.159~171 (2010)
14. Swerdlow RH, "The Alzheimer's disease mitochondrial cascade hypothesis : progress and perspectives", Biochim Biophys Acta, 1842, pp.1219~1231 (2014)
15. Farlow MR, "Treatment options in Alzheimer's disease : maximizing benefit, managing expectations", Dement Geriatr Cogn Disord, 25, pp.408~422 (2008)
16. Moehle EA, "Mitochondrial proteostasis in the context of cellular and organismal health and aging", J Biol Chem, 294, pp.5396~5407 (2019)
17. Tatsuta T, "Quality control of mitochondria : protection against neurodegeneration and ageing", EMBO J, 27, pp.306~314 (2008)
18. Franco-Iborra S, "Mitochondrial Quality Control in Neurodegenerative Diseases : Focus on Parkinson's Disease and Huntington's Disease", Front Neurosci, 12, pp.342~ (2018)
19. Tilokani L, "Mitochondrial dynamics : overview of molecular mechanisms", Essays Biochem, 62, pp.341~360 (2018)
20. Burte F, "Disturbed mitochondrial dynamics and neurodegenerative disorders", Nat Rev Neurol, 11, pp.11~24 (2015)
21. Kandimalla R, "Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis", Biochim Biophys Acta, 1862, pp.814~828 (2016)
22. Reddy PH, "Amyloid beta, mitochondrial dysfunction and synaptic damage : implications for cognitive decline in aging and Alzheimer's disease", Trends Mol Med, 14, pp.45~53 (2008)
23. Manczak M, "Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons : implications for mitochondrial dysfunction and neuronal damage", Hum Mol Genet, 21, pp.2538~2547 (2012)
24. Silva DF, "Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines", Hum Mol Genet, 22, pp.3931~3946 (2013)
25. Calkins MJ, "Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease", Hum Mol Genet, 20, pp.4515~4529 (2011)
26. Manczak M, "Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease : implications for neuronal damage", Hum Mol Genet, 20, pp.2495~2509 (2011)
27. Cassidy-Stone A, "Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax", Bak-dependent mitochondrial outer membrane permeabilization, 2008, pp.14, 193~204
28. Wang W, "Inhibition of mitochondrial fragmentation protects against Alzheimer's disease in rodent model", Hum Mol Genet, 26, pp.4118~4131 (2017)
29. Baek SH, "Inhibition of Drp1Ameliorates Synaptic Depression, Abeta Deposition, and Cognitive Impairment in an Alzheimer's Disease Model", J Neurosci, 37, pp.5099~5110 (2017)
30. Guo X, "Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration", J Clin Invest, 123, pp.5371~5388 (2013)
31. Qi X, "A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity", J Cell Sci, 126, pp.789~802 (2013)
32. Numadate A, "Development of 2-thioxoquinazoline-4-one derivatives as dual and selective inhibitors of dynaminrelated protein 1(Drp1)and puromycin-sensitive aminopeptidase(PSA)", Chem Pharm Bull(Tokyo), 62, pp.979~988 (2014)
33. Mallat A, "Discovery and characterization of selective small molecule inhibitors of the mammalian mitochondrial division dynamin, DRP1", Biochem Biophys Res Commun, 499, pp.556~562 (2018)
34. Kuruva CS, "Aqua-soluble DDQ reduces the levels of Drp1 and Abeta and inhibits abnormal interactions between Abeta and Drp1 and protects Alzheimer's disease neurons from Abeta-and Drp1-induced mitochondrial and synaptic toxicities", Hum Mol Genet, 26, pp.3375~3395 (2017)
35. Smith G, "To mdivi-1 or not to mdivi-1:Is that the question?", Dev Neurobiol, 77, pp.1260~1268 (2017)
36. Valente EM, "Hereditary early-onset Parkinson's disease caused by mutations in PINK1", Science, 304, pp.1158~1160 (2004)
37. Pickrell AM, "The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease", Neuron, 85, pp.257~273 (2015)
38. Du F, "PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease", Brain, 140, pp.3233~3251 (2017)
39. Fang EF, "Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer's disease", Nat Neurosci, 22, pp.401~412 (2019)
40. Andreux PA, "The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans", Nat Metab, 1, pp.595~ (2019)
41. Lambourne OA, "Chemical Strategies for Activating PINK1, a Protein Kinase Mutated in Parkinson's Disease", Chembiochem, 19, pp.2433~2437 (2018)
42. Hertz NT, "A neo-substrate that amplifies catalytic activity of parkinson's-diseaserelated kinase PINK1", Cell, 154, pp.737~747 (2013)
43. Osgerby L, "Kinetin Riboside and Its ProTides Activate the Parkinson's Disease Associated PTEN-Induced Putative Kinase 1(PINK1)Independent of Mitochondrial Depolarization", J Med Chem, 60, pp.3518~3524 (2017)
44. Barini E, "The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1", Chembiochem, 19, pp.425~429 (2018)
45. Halestrap AP, "What is the mitochondrial permeability transition pore?", J Mol Cell Cardiol, 46, pp.821~831 (2009)
46. Baines CP, "Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death", Nature, 434, pp.658~662 (2005)
47. Du H, "Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease", Nat Med, 14, pp.1097~1105 (2008)
48. Du H, "Cyclophilin D deficiency improves mitochondrial function and learning", memory in aging Alzheimer disease mouse model, 2011, pp.32, 398~406
49. Briston T, "Mitochondrial Permeability Transition : A Molecular Lesion with Multiple Drug Targets", Trends Pharmacol Sci, 40, pp.50~70 (2019)
50. Elkamhawy A, "Novel quinazoline-urea analogues as modulators for Abeta-induced mitochondrial dysfunction : design, synthesis, and molecular docking study", Eur J Med Chem, 84, pp.466~475 (2014)
51. Valasani KR, "Identification of a Small Molecule Cyclophilin D Inhibitor for Rescuing Abeta-Mediated Mitochondrial Dysfunction", ACS Med Chem Lett, 7, pp.294~299 (2016)
52. Valasani KR, "Structure based design, synthesis, pharmacophore modeling, virtual screening, and molecular docking studies for identification of novel cyclophilin D inhibitors", J Chem Inf Model, 54, pp.902~912 (2014)
53. Park I, "Discovery of non-peptidic small molecule inhibitors of cyclophilin D as neuroprotective agents in Abeta-induced mitochondrial dysfunction", J Comput Aided Mol Des, 31, pp.929~941 (2017)
54. Paul SM, "Neuroactive steroids", FASEB J, 6, pp.2311~2322 (1992)
55. Porcu P, "Neurosteroidogenesis Today : Novel Targets for Neuroactive Steroid Synthesis and Action and Their Relevance for Translational Research", J Neuroendocrinol, 28, pp.12351~ (2016)
56. Rupprecht R, "Translocator protein(18 kDa)(TSPO)as a therapeutic target for neurological and psychiatric disorders", Nat Rev Drug Discov, 9, pp.971~988 (2010)
57. Banati RB, "Positron emission tomography and functional characterization of a complete PBR", TSPO knockout, 2014, pp.5, 5452~
58. Li J, "Peripheral benzodiazepine receptor ligand, PK11195 induces mitochondria cytochrome c release and dissipation of mitochondria potential via induction of mitochondria permeability transition", Eur J Pharmacol, 560, pp.117~122 (2007)
59. Sileikyte J, "Regulation of the mitochondrial permeability transition pore by the outer membrane does not involve the peripheral benzodiazepine receptor(Translocator Protein of 18 kDa(TSPO))", J Biol Chem, 289, pp.13769~13781 (2014)
60. Selvaraj V, "The changing landscape in translocator protein(TSPO)function", Trends Endocrinol Metab, 26, pp.341~348 (2015)
61. Barron AM, "Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease", J Neurosci, 33, pp.8891~8897 (2013)
62. Kim T, "Discovery of benzimidazole derivatives as modulators of mitochondrial function : A potential treatment for Alzheimer's disease", Eur J Med Chem, 125, pp.1172~1192 (2017)
63. Monga S, "Inhibitory Effects of the Two Novel TSPO Ligands 2-Cl-MGV-1 and MGV-1 on LPS-induced Microglial Activation", Cells, 8, pp.486~ (2019)
64. Yang SY, "Hydroxysteroid(17beta)dehydrogenase X in human health and disease", Mol Cell Endocrinol, 343, pp.1~6 (2011)
65. Yang SY, "Roles of 17beta-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders", J Steroid Biochem Mol Biol, 143, pp.460~472 (2014)
66. He XY, "Intracellular oxidation of allopregnanolone by human brain type 1017beta-hydroxysteroid dehydrogenase", Brain Res, 1040, pp.29~35 (2005)
67. Lustbader JW, "ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease", Science, 304, pp.448~452 (2004)
68. Morsy A, "Amyloid-Binding Alcohol Dehydrogenase(ABAD)Inhibitors for the Treatment of Alzheimer's Disease", J Med Chem, 62, pp.4252~4264 (2019)
69. Boutin S, "Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17beta-hydroxysteroid dehydrogenase type 10", Bioorg Med Chem Lett, 28, pp.3554~3559 (2018)
70. Lim YA, "Inhibition of the mitochondrial enzyme ABAD restores the amyloid-betamediated deregulation of estradiol", PLoS One, 6, pp.e28887~ (2011)
71. Valasani KR, "Structure-based design and synthesis of benzothiazole phosphonate analogues with inhibitors of human ABAD-Abeta for treatment of Alzheimer's disease", Chem Biol Drug Des, 81, pp.238~249 (2013)
72. Benek O, "6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD", 17beta-HSD10 and potential drugs for Alzheimer's disease treatment : Design, synthesis and in vitro evaluation, 2017, pp.13, 345~358
73. Viswanath ANI, "In silico-designed novel non-peptidic ABAD LD hot spot mimetics reverse Abeta-induced mitochondrial impairments in vitro", Chem Biol Drug Des, 90, pp.1041~1055 (2017)
74. Holmstrom KM, "Cellular mechanisms and physiological consequences of redox-dependent signalling", Nat Rev Mol Cell Biol, 15, pp.411~421 (2014)
75. Tonnies E, "Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease", J Alzheimers Dis, 57, pp.1105~1121 (2017)
76. Cheignon C, "Oxidative stress and the amyloid beta peptide in Alzheimer's disease", Redox Biol, 14, pp.450~464 (2018)
77. Barnham KJ, "Biological metals and metal-targeting compounds in major neurodegenerative diseases", Chem Soc Rev, 43, pp.6727~6749 (2014)
78. Dumont M, "Coenzyme Q10decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease", J Alzheimers Dis, 27, pp.211~223 (2011)
79. Gugliandolo A, "Role of Vitamin E in the Treatment of Alzheimer's Disease : Evidence from Animal Models", Int J Mol Sci, 18, pp.2504~ (2017)
80. McManus MJ, "The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease", J Neurosci, 31, pp.15703~15715 (2011)
81. Covey MV, "Effect of the mitochondrial antioxidant, Mito Vitamin E, on hypoxic-ischemic striatal injury in neonatal rats : a dose-response and stereological study", Exp Neurol, 199, pp.513~519 (2006)
82. Webb M, "Modulation of mitochondrial dysfunction for treatment of disease", Bioorg Med Chem Lett, 29, pp.1270~1277 (2019)
83. Oliver DMA, "Small molecules as therapeutic drugs for Alzheimer's disease", Mol Cell Neurosci, 96, pp.47~62 (2019)
84. El-Hattab AW, "Therapies for mitochondrial diseases and current clinical trials", Mol Genet Metab, 122, pp.1~9 (2017)

관련 논문AI추천